Please wait while the formulary information is being retrieved.
IBSRELA (tenapanor HCl)
- irritable bowel syndrome with constipation
50 mg tablet
- 1 tablet (50 mg) by oral route 2 times per day
Default screening record
- 1 tablet (50 mg) by oral route 2 times per day
- None
Contraindicated
- None
Severe
Moderate
- None
- Gastrointestinal obstruction
Contraindicated
- None
Severe
Moderate
- None
IBSRELA (tenapanor HCl)
- irritable bowel syndrome with constipation
- None
- Abdominal distension
- Diarrhea
- Dizziness
- Flatulence
More Frequent
Severe
Less Severe
- None
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Dehydration
- Rectal bleeding
Less Severe
- Bowel sounds hyperactive
Contraindicated
Tenapanor
Contraindicated in age < 6 years per manufacturer due to risk of serious dehydration.
- 1 Day – 6 Years
- 1 Contraindicated in age < 6 years per manufacturer due to risk of serious dehydration.
Severe Precaution
Tenapanor
Avoid use in age < 12 years due to risk of serious dehydration
- 6 Years – 12 Years
- Avoid use in age < 12 years due to risk of serious dehydration
Management or Monitoring Precaution
Tenapanor
Safety and effectiveness not established; risk of serious dehydration.
- 12 Years – 18 Years
- Safety and effectiveness not established; risk of serious dehydration.
Tenapanor
- Severity Level:
2
- Additional Notes: Minimal systemic absorption; fetal exposure not expected
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
Tenapanor
Minimal sys absorp will not result in relevant exposure to breastfed infant.
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Unknown | No adverse effect | Minimal sys absorp will not result in relevant exposure to breastfed infant. |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- This medication must not be used by children younger than 6 years. It is not recommended for use by children who are 6 to less than 18 years due to the risk for harm (especially serious dehydration). Talk to your doctor for details.
| Constipation predominant irritable bowel syndrome | |
| K58.1 | Irritable bowel syndrome with constipation |
| 0-9 | A-Z |
|---|---|
| K58.1 | Irritable bowel syndrome with constipation |
Formulary Reference Tool